Kangstem Biotech (CEO Na Jong-cheon) participated in ‘BIO KOREA 5’ held at COEX, Seoul for three days from May 10 (Wed) to 12 (Fri).
Kangstem Biotech is a domestic biopharmaceutical company that was established in 2010 as ‘Kangstem Holdings’ and started its business. After 10 years, it started a cell therapy-based CDMO business with a license as an advanced biopharmaceutical manufacturer, and has won a total of four projects so far.
These include △ limbal stem cell therapy for ophthalmology being developed for the first time in Korea △ cell therapy differentiated into neural progenitor cells for patients with chronic spinal cord injury △ production and quality testing of exosomes for wound care △ regenerating blood for loading mRNA (messenger ribonucleic acid) Various CDMO projects such as stem cells were included.
In this way, Kangstem Biotech, which is expanding its CDMO business to the field of gene therapy, focused on promoting its CDMO capabilities in this exhibition as well. At the same time, stem cell culture media and cell freezing/thawing platforms were also introduced, attracting the attention of visitors.
In addition to this, Kangstem Biotech is also operating a service that develops and builds a mass production process for commercialization beyond small-scale production of clinical products.
In addition, Kangstem Bio explains that it has the know-how to maintain healthy cells that do not decrease in cell number and activity even during mass production. Through this, a 100-liter mass production process for wound care products using exosomes was established, and by securing a cell bank in-house, product safety, maintenance of uniform efficacy, and product consistency, which are important in the development of treatments, are guaranteed.
An official from Kangstem Biotech said, “We are actively promoting our CDMO capabilities to domestic and foreign buyers, discussing directly with companies requesting consultations on site, and working hard to win additional orders in the future.” We would like to inform our customers that we are providing excellent service based on the experience of numerous clinical trials accumulated over the period of time,” said the reason for participating in this exhibition.
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th this year, was hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. Since 2006, BIO KOREA, which has been striving to promote the global status and continuous growth of the Korean health industry, has been strengthening its position as Korea’s representative bio-health international convention with world-renowned scholars and business experts participating every year. BIO KOREA 2023, together with domestic and foreign companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as companies and institutions of interest such as consulting, academia, and related organizations, offers various programs such as conferences, business partnering, exhibitions, and invest fairs. It goes on.